Efficacy and safety of abatacept for interstitial lung disease associated with antisynthetase syndrome: a case series
CONCLUSIONS: Our study offers preliminary, but encouraging, clinical evidence in favour of ABA as a therapy for ASS-ILD. ABA demonstrated favourable effects on ILD and was well-tolerated. Well-designed randomised controlled studies are required to confirm the efficacy and safety of this strategy.PMID:38079347 | DOI:10.55563/clinexprheumatol/53puzu (Source: Clinical and Experimental Rheumatology)
Source: Clinical and Experimental Rheumatology - December 11, 2023 Category: Rheumatology Authors: Nana Xia Soon-Min Hong Xueliang Zhang Chenyi Shao Ninghui Yan Huihua Ding Qiang Guo Source Type: research
Factors associated with mental illness in patients with rheumatoid arthritis initiating b/ts DMARDs: A population ‐based study
ConclusionThis population-based study investigated the incidence and factors associated with mental illness among patients with RA receiving b/tsDMARDs. Our findings highlight the need for vigilance with respect to the possibility of mental illness in patients with RA. (Source: International Journal of Rheumatic Diseases)
Source: International Journal of Rheumatic Diseases - December 8, 2023 Category: Rheumatology Authors: Hsin ‐Hua Chen,
Peng‐Yen Wu,
Ching‐Heng Lin,
Chieh‐Liang Wu,
Wen‐Cheng Chao Tags: ORIGINAL ARTICLE Source Type: research
Treatment of Adults Hospitalized With COVID-19 Pneumonia
To the Editor We have several comments about the recent randomized clinical trial (ACTIV-1) that investigated the effect of abatacept, cenicriviroc, or infliximab on COVID-19 pneumonia. (Source: JAMA)
Source: JAMA - December 5, 2023 Category: General Medicine Source Type: research
ADA_ETA_BIO2021: real-world evaluation of adherence, persistence, and cost-effectiveness of originator and biosimilar biologic drugs in the treatment of rheumatoid arthritis: a multicenter study in Italy
CONCLUSIONS: This multicentre retrospective observational study of bDMARDs used in the treatment of RA showed that, for all the drugs studied, there was no problem with adherence to treatment but rather a difficulty in maintaining treatment with the same drug over time.PMID:37994874 | DOI:10.1080/03007995.2023.2287600 (Source: Current Medical Research and Opinion)
Source: Current Medical Research and Opinion - November 23, 2023 Category: Research Authors: Fiorenzo Santoleri Ruggero Lasala Paolo Abrate Laura Pestrin Enrico Pasut Germana Modesti Felice Musicco Chiara Fulgenzio Eva Zuzolo Gabriella Pieri Martina Roperti Pietro Gazzola Marco Gambera Isabella Martignoni Valentina Montresor Francesco De Vita Fra Source Type: research
How should we approach management of childhood onset chronic anterior uveitis refractory to adalimumab?
Expert Rev Clin Immunol. 2023 Nov 21. doi: 10.1080/1744666X.2023.2284845. Online ahead of print.ABSTRACTINTRODUCTION: The management of refractory juvenile idiopathic associated uveitis (JIAU) or childhood-onset chronic anterior uveitis (CAU) is a challenge. There is no clear consensus or evidence base for to suggest the most appropriate therapy after primary or secondary failure of biweekly adalimumab. In this scenario, most clinicians advocate switching to another anti-tumor necrosis factor alpha inhibitor, however, there are a variety of other disease modifying agents to choose from albeit with a differing levels of evi...
Source: Expert Review of Clinical Immunology - November 22, 2023 Category: Allergy & Immunology Authors: Ivan Foeldvari Harry Petrushkin Source Type: research
